Acute Respiratory Distress Syndrome (ARDS): Global Market Insights, Epidemiology & Forecast to 2028 - ResearchAndMarkets.com

DUBLIN--()--The "Acute Respiratory Distress Syndrome (ARDS) - Market Insights, Epidemiology, and Market Forecast - 2028" drug pipelines has been added to ResearchAndMarkets.com's offering.

This report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of ARDS in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The report provides the current treatment practices, emerging drugs, market share of the individual therapies, the current and forecasted market size of ARDS from 2017 to 2028 segmented by the seven major markets.

In the current scenario, there is no US Food and Drug Administration (FDA) approved drugs present in the market, specifically for this indication, the availability of new therapies will be the major market driver for the therapeutic market of ARDS. Despite decades of research, treatment options for ARDS are restricted. Supportive care with mechanical ventilation remains the mainstay of management.

Although emerging therapies, like Traumakine (Faron Pharmaceuticals), BIO-11006 (BioMarck Pharmaceuticals), MultiStem (Athersys), Solnatide (Apeptico), which is in the pipeline and are expected to launch during the forecast period [2019-2028]. Due to the unavailability of approved drugs, the launch of emerging therapies will create a huge hype.

Additionally, the increasing incidence, awareness of the disease and promising emerging pipeline therapies will propel the market size forward during the forecast period of 2019-2028.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2028

Acute Respiratory Distress Syndrome (ARDS) - Epidemiology

The ARDS epidemiology division provides insights about historical and current patient pool and forecasted trends for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders (KOL). This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented by Total Incident Population of Acute Respiratory Distress Syndrome in the 7MM, Severity Specific Incident Population of Acute Respiratory Distress Syndrome in the 7MM and Incident Population of Acute Respiratory Distress Syndrome by Risk Factors in the 7MM] scenario of ARDS in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017 to 2028.

As per this analysis, the total Incident Population of Acute Respiratory Distress Syndrome (ARDS) in the 7MM was found to be 815,490 in 2017 and expected to increase during the forecast period of 2017-2028. The estimates show the incidence was higher in the United States and among the EU-5 countries, Germany had the highest incident population of ARDS followed by Italy.

On the other hand, Spain had the lowest incident population of ARDS. Another estimate of this analysis shows that in terms of severity-specific incidence, a similar trend is observed in all countries, with the majority of the cases witnessed for moderate ARDS, except France, where severe cases of ARDS accounted for a maximum patient population. Furthermore, the highest number of incident cases were assessed for ARDS due to Pneumonia, in all the 7MM countries, except the United Kingdom, in which Sepsis was the primary risk factor for ARDS.

Acute Respiratory Distress Syndrome (ARDS) - Drug Chapters

This segment of the Acute Respiratory Distress Syndrome report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

At present, there is no marketed drug for the treatment of ARDS and the market of ARDS is dependent on the supportive as well as emerging therapies. In order to meet the high unmet need of ARDS treatment regimen, companies across the globe have shifted their focus toward this therapeutic area. The overall dynamics of ARDS market is anticipated to change in the coming years owing to the expected launch of emerging therapies. Key players in the market of ARDS are Faron Pharmaceuticals, Techpool Bio-Pharma, BioMarck Pharmaceuticals, Athersys, Apeptico Forschung und Entwicklung GmbH, and others.

Interferon-beta-1a (Traumakine) is under development by Faron Pharmaceuticals, as its lead drug candidate. It is a lyophilized powder form of recombinant human IFN beta-1a reconstituted in water for injection. It targets the Interferon-beta receptor 1, activating its action and is being administered intravenously. This drug received Fast Track designation from the US Food and Drug Administration (FDA) in 2018. It also been granted orphan drug designation for the treatment of acute respiratory distress syndrome (ARDS).

Faron Pharmaceuticals recently announced that the INTEREST trial did not meet its primary endpoint, nevertheless the treatment benefit was observed in subgroups of patients identified with biomarkers. At present, the company is investigating the root cause and recently, the company stated the final results of YODA studies.

This study was conducted because the post-hoc analysis of the phase III INTEREST study had indicated a significant reduction of interferon-beta (IFN-beta) action by steroids and this finding was also observed in the Japanese phase III study. According to the final results, it was confirmed that the results are consistent with the INTEREST data, supporting the conclusion that co-administration of steroids with Traumakine in patients inhibited interferon-beta action. The company currently investigates that a further Traumakine trial is likely to be funded through third-party funding. Low concomitant corticosteroid use is expected during the INFORAAA trial.

On the other hand, BIO-11006 (BioMarck Pharmaceuticals) is a novel patented peptide that inhibits the myristoylated alanine-rich C kinase substrate (MARCKS) protein. BIO-11006 is an inhalation therapy of 28 days, for the treatment of moderate to severe ARDS. BIO-11006 is part of a portfolio of over 100 patented compounds owned by Biomarck. Lately, the company reported that the first patients have been treated with BIO-11006 in Phase II clinical study for patients with ARDS.

MultiStem (Athersys), which recently received Fast Track designation for its clinical program evaluating MultiStem cell therapy for the treatment of Acute ARDS. The phase II clinical trial for this drug is currently ongoing to evaluate the efficacy and safety of HLCM051 (MultiStem) in patients with ARDS. This is a patented regenerative product that has the ability to promote tissue repair and healing in a variety of ways, such as through the production of multiple therapeutic factors produced in response to signals of inflammation and tissue damage and restore immune system balance.

Solnatide, by Apeptico, is a synthetic molecule whose structure is based on the lectin-like domain of the human Tumour Necrosis Factor a. This peptide is water-soluble and can be administered into the lung by oral inhalation. Currently, it is in phase IIb clinical trial which will be expected to complete in December 2019. In previous trial results, it was stated that tolerability and safety of the treatment were generally good. It is also been granted with Orphan drug status.

Acute Respiratory Distress Syndrome (ARDS) - Market Outlook

The ARDS market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.

This segment gives a thorough detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market, and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

In recent years, many pharmaceutical companies started working on this indication but there is no approved therapy present for the treatment of acute respiratory distress syndrome (ARDS). The current therapeutic market is driven by supportive therapies.

According to this research, the market size of ARDS was USD 932.8 million in 2017. The current therapeutic market of ARDS is 7MM is dependent on supportive pharmacologic treatment regimens and mechanical ventilation but the expected launch of potential therapies may increase the market size in the coming years, assisted by an increase in the incident population of ARDS and awareness of the disease.

It is also attributed that the market of ARDS based on supportive pharmacologic therapies Inhaled vasodilators occupied the majority of the market share in the 7MM countries, followed by Neuromuscular Blockade, and Corticosteroids. Among the 7MM countries, the United States accounted for the highest market size for ARDS of the total 7MM market in comparison to EU5 and Japan.

Another modest increase in market size of currently prescribed therapies has been witnessed initially, with a consistent decrease, thereafter, owing to the increasing demand for targeted therapies to treat ARDS and thereby expected the launch of therapies during the forecast period [2019-2028].

Expected launch of Traumakine (Faron Pharmaceuticals), MultiStem (Athersys), BIO-11006 (BioMarck Pharmaceuticals), and Solnatide (APEPTICO), for the treatment of ARDS, during the forecast period [2019-2028] will create a positive impact on ARDS treatment market.

Acute Respiratory Distress Syndrome (ARDS) - Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017 to 2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The dynamics of ARDS market are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the diseases, incremental healthcare spending across the world and expected the launch of emerging therapies during the forecast period of 2019-2028. Companies across the globe are thoroughly working toward the development of new treatment therapies for ARDS.

The overall dynamics of ARDS market are anticipated to change in the coming years owing to the expected launch of emerging therapies. Key players in the market of ARDS are Faron Pharmaceuticals, Techpool Bio-Pharma, BioMarck Pharmaceuticals, Athersys, Apeptico Forschung und Entwicklung GmbH, United Therapeutics, and others. Emerging therapies, in the late clinical development, are focused on the treatment of ARDS and hence are expected to create a significant impact on market size. These include Traumakine (Faron Pharmaceuticals), BIO-11006 (BioMarck Pharmaceuticals), MultiStem (Athersys), AP301 (Apeptico) and are expected to launch during the forecast period [2019-2028].

Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Report Key Strengths

  • 10 Years Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Key Cross Competition
  • Market Size by Therapies
  • Drugs Uptake

Report Assessment

  • Pipeline Product Profiles
  • Key Products and Key Players
  • Market Drivers and Barriers

Key Benefits

  • This report will help to develop Business Strategies by understanding the trends shaping and driving Acute Respiratory Distress Syndrome (ARDS) market
  • Organize sales and marketing efforts by identifying the best opportunities for ARDS market
  • To understand the future market competition in the ARDS market

Companies Mentioned

  • Faron Pharmaceuticals (Traumakine)
  • Athersys (MultiStem)
  • BioMarck Pharmaceuticals (BIO-11006)
  • Apeptico (AP301)
  • United Therapeutics (Remodulin)
  • Techpool Bio-Pharma (Ulinastatin)

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/ppv36v

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900